{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T04:25:03Z","timestamp":1768278303328,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,6]],"date-time":"2011-04-06T00:00:00Z","timestamp":1302048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1007\/s11095-011-0409-6","type":"journal-article","created":{"date-parts":[[2011,4,5]],"date-time":"2011-04-05T19:58:04Z","timestamp":1302033484000},"page":"1733-1749","source":"Crossref","is-referenced-by-count":54,"title":["PLGA Microparticles Encapsulating Prostaglandin E1-Hydroxypropyl-\u03b2-cyclodextrin (PGE1-HP\u03b2CD) Complex for the Treatment of Pulmonary Arterial Hypertension (PAH)"],"prefix":"10.1007","volume":"28","author":[{"given":"Vivek","family":"Gupta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marauo","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louisa J.","family":"Hope-Weeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fakhrul","family":"Ahsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,6]]},"reference":[{"key":"409_CR1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0169-409X(98)00058-1","volume":"36","author":"F Hirayama","year":"1999","unstructured":"Hirayama F, Uekama K. Cyclodextrin-based controlled drug release system. Adv Drug Deliv Rev. 1999;36:125\u201341.","journal-title":"Adv Drug Deliv Rev"},{"key":"409_CR2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/js960213f","volume":"86","author":"T Irie","year":"1997","unstructured":"Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86:147\u201362. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation.","journal-title":"J Pharm Sci"},{"key":"409_CR3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0192623307310945","volume":"36","author":"VJ Stella","year":"2008","unstructured":"Stella VJ, He Q. Cyclodextrins. Toxicol Pathol. 2008;36:30\u201342.","journal-title":"Toxicol Pathol"},{"key":"409_CR4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.fct.2005.03.007","volume":"43","author":"S Gould","year":"2005","unstructured":"Gould S, Scott RC. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): a toxicology review. Food Chem Toxicol. 2005;43:1451\u20139.","journal-title":"Food Chem Toxicol"},{"key":"409_CR5","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/03639040801926063","volume":"34","author":"M Jug","year":"2008","unstructured":"Jug M, Becirevic-Lacan M. Development of a cyclodextrin-based nasal delivery system for lorazepam. Drug Dev Ind Pharm. 2008;34:817\u201326.","journal-title":"Drug Dev Ind Pharm"},{"key":"409_CR6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jps.2600840220","volume":"84","author":"TO Carpenter","year":"1995","unstructured":"Carpenter TO, Gerloczy A, Pitha J. Safety of parenteral hydroxypropyl beta-cyclodextrin. J Pharm Sci. 1995;84:222\u20135.","journal-title":"J Pharm Sci"},{"key":"409_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0005-2760(69)90001-0","volume":"187","author":"J Kloeze","year":"1969","unstructured":"Kloeze J. Relationship between chemical structure and platelet-aggregation activity of prostaglandins. Biochim Biophys Acta. 1969;187:285\u201392.","journal-title":"Biochim Biophys Acta"},{"key":"409_CR8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1203\/01.PDR.0000139927.86617.B6","volume":"56","author":"BG Sood","year":"2004","unstructured":"Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a Phase I\/II open label clinical trial. Pediatr Res. 2004;56:579\u201385.","journal-title":"Pediatr Res"},{"key":"409_CR9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0889-8553(21)00052-2","volume":"21","author":"JL Wallace","year":"1992","unstructured":"Wallace JL. Prostaglandins, NSAIDs, and cytoprotection. Gastroenterol Clin North Am. 1992;21:631\u201341.","journal-title":"Gastroenterol Clin North Am"},{"key":"409_CR10","unstructured":"Della Rocca G, Coccia C, Pompei L, Costa MG, Di Marco P, Pietropaoli P. Inhaled aerosolized prostaglandin E1, pulmonary hemodynamics, and oxygenation during lung transplantation. Minerva Anestesiol. 2008;74:627\u2013633."},{"key":"409_CR11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0168-3659(00)00373-4","volume":"71","author":"R Igarashi","year":"2001","unstructured":"Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo-AS013) due to vascular wall targeting. J Control Release. 2001;71:157\u201364.","journal-title":"J Control Release"},{"key":"409_CR12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00000542-199809000-00019","volume":"89","author":"K Nakazawa","year":"1998","unstructured":"Nakazawa K, Uchida T, Matsuzawa Y, Yokoyama K, Makita K, Amaha K. Treatment of pulmonary hypertension and hypoxia due to oleic acid induced lung injury with intratracheal prostaglandin E1 during partial liquid ventilation. Anesthesiology. 1998;89:686\u201392.","journal-title":"Anesthesiology"},{"key":"409_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/PL00007632","volume":"177","author":"F Sakuma","year":"1999","unstructured":"Sakuma F, Miyata M, Kasukawa R. Suppressive effect of prostaglandin E1 on pulmonary hypertension induced by monocrotaline in rats. Lung. 1999;177:77\u201388.","journal-title":"Lung"},{"key":"409_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2004.11.021","volume":"290","author":"FG Gu","year":"2005","unstructured":"Gu FG, Cui FD, Gao YL. Preparation of prostaglandin E1-hydroxypropyl-beta-cyclodextrin complex and its nasal delivery in rats. Int J Pharm. 2005;290:101\u20138.","journal-title":"Int J Pharm"},{"key":"409_CR15","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1023\/A:1013034615464","volume":"18","author":"K Uekama","year":"2001","unstructured":"Uekama K, Hieda Y, Hirayama F, Arima H, Sudoh M, Yagi A, et al. Stabilizing and solubilizing effects of sulfobutyl ether beta-cyclodextrin on prostaglandin E1 analogue. Pharm Res. 2001;18:1578\u201385.","journal-title":"Pharm Res"},{"key":"409_CR16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jps.2600800213","volume":"80","author":"M Wiese","year":"1991","unstructured":"Wiese M, Cordes HP, Chi H, Seydel JK, Backensfeld T, Muller BW. Interaction of prostaglandin E1 with alpha-cyclodextrin in aqueous systems: stability of the inclusion complex. J Pharm Sci. 1991;80:153\u20136.","journal-title":"J Pharm Sci"},{"key":"409_CR17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1248\/cpb.40.747","volume":"40","author":"M Yamamoto","year":"1992","unstructured":"Yamamoto M, Hirayama F, Uekama K. Improvement of stability and dissolution of prostaglandin E1 by maltosyl-beta-cyclodextrin in lyophilized formulation. Chem Pharm Bull Tokyo. 1992;40:747\u201351.","journal-title":"Chem Pharm Bull Tokyo"},{"key":"409_CR18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1213\/00000539-199804000-00015","volume":"86","author":"J Meyer","year":"1998","unstructured":"Meyer J, Theilmeier G, Van Aken H, Bone HG, Busse H, Waurick R, et al. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg. 1998;86:753\u20138.","journal-title":"Anesth Analg"},{"key":"409_CR19","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/jps.21946","volume":"99","author":"V Gupta","year":"2010","unstructured":"Gupta V, Rawat A, Ahsan F. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci. 2010;99:1774\u201389.","journal-title":"J Pharm Sci"},{"key":"409_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/10611869808997878","volume":"6","author":"E Marttin","year":"1998","unstructured":"Marttin E, Verhoef JC, Merkus FW. Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target. 1998;6:17\u201336.","journal-title":"J Drug Target"},{"key":"409_CR21","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/B:PHAM.0000032998.84488.7a","volume":"21","author":"T Yang","year":"2004","unstructured":"Yang T, Hussain A, Paulson J, Abbruscato TJ, Ahsan F. Cyclodextrins in nasal delivery of low-molecular-weight heparins: in vivo and in vitro studies. Pharm Res. 2004;21:1127\u201336.","journal-title":"Pharm Res"},{"key":"409_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0378-5173(00)00335-5","volume":"197","author":"DC Bibby","year":"2000","unstructured":"Bibby DC, Davies NM, Tucker IG. Mechanisms by which cyclodextrins modify drug release from polymeric drug delivery systems. Int J Pharm. 2000;197:1\u201311.","journal-title":"Int J Pharm"},{"key":"409_CR23","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2004.09.030","volume":"102","author":"G Rosa De","year":"2005","unstructured":"De Rosa G, Larobina D, Immacolata La Rotonda M, Musto P, Quaglia F, Ungaro F. How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin\/hydroxypropyl-beta-cyclodextrin system. J Control Release. 2005;102:71\u201383.","journal-title":"J Control Release"},{"key":"409_CR24","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jconrel.2008.03.013","volume":"128","author":"A Rawat","year":"2008","unstructured":"Rawat A, Majumder QH, Ahsan F. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release. 2008;128:224\u201332.","journal-title":"J Control Release"},{"key":"409_CR25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2008.12.011","volume":"135","author":"F Ungaro","year":"2009","unstructured":"Ungaro F, d'Emmanuele di Villa Bianca R, Giovino C, Miro A, Sorrentino R, Quaglia F, et al. Insulin-loaded PLGA\/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release. 2009;135:25\u201334.","journal-title":"J Control Release."},{"key":"409_CR26","unstructured":"Gonda I. Physico-chemical principles in aerosol delivery. In D J A Crommelinand K.K. Midha (eds.), Topics in Pharmaceutical Sciences, Medpharm GmbH Scientific Publisher, Stuttgart, 1991, pp. 95\u2013115."},{"key":"409_CR27","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.biomaterials.2008.12.044","volume":"30","author":"Y Yang","year":"2009","unstructured":"Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30:1947\u201353.","journal-title":"Biomaterials"},{"key":"409_CR28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/sca.20147","volume":"31","author":"SK Gill","year":"2009","unstructured":"Gill SK, Shobe AM, Hope-Weeks LJ. Synthesis of cobalt oxide aerogels and nanocomposite systems containing single-walled carbon nanotubes. Scanning. 2009;31:132\u20138.","journal-title":"Scanning"},{"key":"409_CR29","first-page":"447","volume":"36","author":"OR Moss","year":"1979","unstructured":"Moss OR. Simulants of lung interstitial fluid. Health Phys. 1979;36:447\u20138.","journal-title":"Health Phys"},{"key":"409_CR30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11095-005-8926-9","volume":"23","author":"A Hussain","year":"2006","unstructured":"Hussain A, Majumder QH, Ahsan F. Inhaled insulin is better absorbed when administered as a dry powder compared to solution in the presence or absence of alkylglycosides. Pharm Res. 2006;23:138\u201347.","journal-title":"Pharm Res"},{"key":"409_CR31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/jps.21069","volume":"97","author":"C Thomas","year":"2008","unstructured":"Thomas C, Rawat A, Bai S, Ahsan F. Feasibility study of inhaled hepatitis B vaccine formulated with tetradecylmaltoside. J Pharm Sci. 2008;97:1213\u201323.","journal-title":"J Pharm Sci"},{"key":"409_CR32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0041-008X(92)90317-L","volume":"115","author":"AL Nieminen","year":"1992","unstructured":"Nieminen AL, Gores GJ, Bond JM, Imberti R, Herman B, Lemasters JJ. A novel cytotoxicity screening assay using a multiwell fluorescence scanner. Toxicol Appl Pharmacol. 1992;115:147\u201355.","journal-title":"Toxicol Appl Pharmacol"},{"key":"409_CR33","doi-asserted-by":"crossref","first-page":"C1783","DOI":"10.1152\/ajpcell.1997.273.6.C1783","volume":"273","author":"T Qian","year":"1997","unstructured":"Qian T, Nieminen AL, Herman B, Lemasters JJ. Mitochondrial permeability transition in pH-dependent reperfusion injury to rat hepatocytes. Am J Physiol. 1997;273:C1783\u201392.","journal-title":"Am J Physiol"},{"key":"409_CR34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0378-4274(02)00134-0","volume":"133","author":"TA Sarafian","year":"2002","unstructured":"Sarafian TA, Kouyoumjian S, Tashkin D, Roth MD. Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. Toxicol Lett. 2002;133:171\u20139.","journal-title":"Toxicol Lett"},{"key":"409_CR35","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1023\/A:1010947631380","volume":"18","author":"EA Zannou","year":"2001","unstructured":"Zannou EA, Streng WH, Stella VJ. Osmotic properties of sulfobutylether and hydroxypropyl cyclodextrins. Pharm Res. 2001;18:1226\u201331.","journal-title":"Pharm Res"},{"key":"409_CR36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/026520400405723","volume":"17","author":"KF Pistel","year":"2000","unstructured":"Pistel KF, Kissel T. Effects of salt addition on the microencapsulation of proteins using W\/O\/W double emulsion technique. J Microencapsul. 2000;17:467\u201383.","journal-title":"J Microencapsul"},{"key":"409_CR37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/02652040400026400","volume":"22","author":"C Srinivasan","year":"2005","unstructured":"Srinivasan C, Katare YK, Muthukumaran T, Panda AK. Effect of additives on encapsulation efficiency, stability and bioactivity of entrapped lysozyme from biodegradable polymer particles. J Microencapsul. 2005;22:127\u201338.","journal-title":"J Microencapsul"},{"key":"409_CR38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0168-3659(98)00185-0","volume":"59","author":"SC Lee","year":"1999","unstructured":"Lee SC, Oh JT, Jang MH, Chung SI. Quantitative analysis of polyvinyl alcohol on the surface of poly(D, L-lactide-co-glycolide) microparticles prepared by solvent evaporation method: effect of particle size and PVA concentration. J Control Release. 1999;59:123\u201332.","journal-title":"J Control Release"},{"key":"409_CR39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/jps.21913","volume":"99","author":"MS Hassan","year":"2010","unstructured":"Hassan MS, Lau R. Feasibility study of pollen-shape drug carriers in dry powder inhalation. J Pharm Sci. 2010;99:1309\u201321.","journal-title":"J Pharm Sci"},{"key":"409_CR40","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1126\/science.276.5320.1868","volume":"276","author":"DA Edwards","year":"1997","unstructured":"Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, et al. Large porous particles for pulmonary drug delivery. Science. 1997;276:1868\u201371.","journal-title":"Science"},{"key":"409_CR41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0378-5173(03)00207-2","volume":"259","author":"YI Jeong","year":"2003","unstructured":"Jeong YI, Song JG, Kang SS, Ryu HH, Lee YH, Choi C, et al. Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm. 2003;259:79\u201391.","journal-title":"Int J Pharm"},{"key":"409_CR42","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejps.2006.05.005","volume":"28","author":"F Ungaro","year":"2006","unstructured":"Ungaro F, De Rosa G, Miro A, Quaglia F, La Rotonda MI. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci. 2006;28:423\u201332.","journal-title":"Eur J Pharm Sci"},{"key":"409_CR43","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/02652049709015330","volume":"14","author":"R Jeyanthi","year":"1997","unstructured":"Jeyanthi R, Mehta RC, Thanoo BC, DeLuca PP. Effect of processing parameters on the properties of peptide-containing PLGA microspheres. J Microencapsul. 1997;14:163\u201374.","journal-title":"J Microencapsul"},{"key":"409_CR44","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(97)00048-3","volume":"28","author":"MS Shive","year":"1997","unstructured":"Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28:5\u201324.","journal-title":"Adv Drug Deliv Rev"},{"key":"409_CR45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1254\/jjp.23.355","volume":"23","author":"J Nakano","year":"1973","unstructured":"Nakano J, Prancan AV, Morsy NH. Metabolism of prostaglandin E1 in stomach, jejunum chyle and plasma of the dog and the rat. Jpn J Pharmacol. 1973;23:355\u201361.","journal-title":"Jpn J Pharmacol"},{"key":"409_CR46","first-page":"177","volume":"4","author":"P Ney","year":"1991","unstructured":"Ney P, Braun M, Szymanski C, Bruch L, Schror K. Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)\u2013an in vivo metabolite of PGE1 in man. Eicosanoids. 1991;4:177\u201384.","journal-title":"Eicosanoids"},{"key":"409_CR47","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0041-008X(78)90191-6","volume":"44","author":"RF Henderson","year":"1978","unstructured":"Henderson RF, Damon EG, Henderson TR. Early damage indicators in the the lung I. Lactate dehydrogenase activity in the airways. Toxicol Appl Pharmacol. 1978;44:291\u20137.","journal-title":"Toxicol Appl Pharmacol"},{"key":"409_CR48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejps.2005.03.006","volume":"25","author":"A Hussain","year":"2005","unstructured":"Hussain A, Ahsan F. State of insulin self-association does not affect its absorption from the pulmonary route. Eur J Pharm Sci. 2005;25:289\u201398.","journal-title":"Eur J Pharm Sci"},{"key":"409_CR49","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0041-008X(82)90057-6","volume":"66","author":"BD Beck","year":"1982","unstructured":"Beck BD, Brain JD, Bohannon DE. An in vivo hamster bioassay to assess the toxicity of particulates for the lungs. Toxicol Appl Pharmacol. 1982;66:9\u201329.","journal-title":"Toxicol Appl Pharmacol"},{"key":"409_CR50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/js960352x","volume":"86","author":"Y Matsukawa","year":"1997","unstructured":"Matsukawa Y, Lee VH, Crandall ED, Kim KJ. Size-dependent dextran transport across rat alveolar epithelial cell monolayers. J Pharm Sci. 1997;86:305\u20139.","journal-title":"J Pharm Sci"},{"key":"409_CR51","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jconrel.2007.11.003","volume":"126","author":"L Matilainen","year":"2008","unstructured":"Matilainen L, Toropainen T, Vihola H, Hirvonen J, Jarvinen T, Jarho P, et al. In vitro toxicity and permeation of cyclodextrins in Calu-3 cells. J Control Release. 2008;126:10\u20136.","journal-title":"J Control Release"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-011-0409-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-011-0409-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-011-0409-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T04:27:49Z","timestamp":1637468869000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-011-0409-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,6]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["409"],"URL":"https:\/\/doi.org\/10.1007\/s11095-011-0409-6","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,6]]}}}